Status:
RECRUITING
Myocardial Work Evaluation in Patients With PAH
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
Right ventricular function is a key determinant of survival in patients with pulmonary arterial hypertension, with right heart failure being the leading cause of death. ERS/ESC guidelines recommend ev...
Detailed Description
Pulmonary arterial hypertension (PAH) is a rare hemodynamic disease characterized by pre-capillary pulmonary hypertension (PH), due to pulmonary vascular remodeling. Despite the recent development of ...
Eligibility Criteria
Inclusion
- All consecutive incident patients with a diagnosis of idiopathic, heritable, drug-associated PH, or associated with portal hypertension and referred to PH reference center in Nancy university hospital.
- Transthoracic echocardiography (TTE) and a right heart catheterization (RHC) within 48 hours at diagnosis and at first reevaluation with PAH treatment
Exclusion
- cardiac ultrasound data not analyzable (poor echogenicity or poor quality of RV slice). - -- Patients with PH associated with left-heart disease (group 2), PH associated with lung diseases and/or hypoxia (group 3), PH associated with pulmonary artery obstructions (group 4) and PH with unclear and/or multifactorial mechanisms (group 5) were also excluded. Patients with a positive response to the vasoreactivity test or with features of venous or capillaries involvement were also excluded.
Key Trial Info
Start Date :
July 25 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06567379
Start Date
July 25 2024
End Date
September 30 2024
Last Update
August 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valentin
Nancy, France